The current standard-of-care therapies, including androgen receptor signaling inhibitors (ARSIs), radiotherapy, and chemotherapies, have exhibited good clinical efficacy, but offer survival benefits only measured in months in advanced PCa patients [1,2]. This evidence concerns the gene AR and posterior cortical atrophy.